Severe Photosensitivity Reaction After Pirfenidone Use

Idiopathic pulmonary fibrosis is a chronic and progressive disease with a significant mortality rate. Pirfenidone is one of two oral antifibrotic therapies approved to treat idiopathic pulmonary fibrosis (IPF). Pirfenidone helps decrease disease progression in patients with IPF and reduces vital cap...

Descripción completa

Detalles Bibliográficos
Autores principales: Choudhury, Saiara, Taweesedt, Pahnwat T, Dadhwal, Rahul, Surani, Salim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Family/General Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384726/
https://www.ncbi.nlm.nih.gov/pubmed/34458037
http://dx.doi.org/10.7759/cureus.16626
_version_ 1783741954289303552
author Choudhury, Saiara
Taweesedt, Pahnwat T
Dadhwal, Rahul
Surani, Salim
author_facet Choudhury, Saiara
Taweesedt, Pahnwat T
Dadhwal, Rahul
Surani, Salim
author_sort Choudhury, Saiara
collection PubMed
description Idiopathic pulmonary fibrosis is a chronic and progressive disease with a significant mortality rate. Pirfenidone is one of two oral antifibrotic therapies approved to treat idiopathic pulmonary fibrosis (IPF). Pirfenidone helps decrease disease progression in patients with IPF and reduces vital capacity. This has led to widespread use of this medication in recent years. In this case report, we present a 60-year-old male who started treatment with pirfenidone for IPF and had severe skin reactions after initiation of therapy.
format Online
Article
Text
id pubmed-8384726
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-83847262021-08-26 Severe Photosensitivity Reaction After Pirfenidone Use Choudhury, Saiara Taweesedt, Pahnwat T Dadhwal, Rahul Surani, Salim Cureus Family/General Practice Idiopathic pulmonary fibrosis is a chronic and progressive disease with a significant mortality rate. Pirfenidone is one of two oral antifibrotic therapies approved to treat idiopathic pulmonary fibrosis (IPF). Pirfenidone helps decrease disease progression in patients with IPF and reduces vital capacity. This has led to widespread use of this medication in recent years. In this case report, we present a 60-year-old male who started treatment with pirfenidone for IPF and had severe skin reactions after initiation of therapy. Cureus 2021-07-25 /pmc/articles/PMC8384726/ /pubmed/34458037 http://dx.doi.org/10.7759/cureus.16626 Text en Copyright © 2021, Choudhury et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Family/General Practice
Choudhury, Saiara
Taweesedt, Pahnwat T
Dadhwal, Rahul
Surani, Salim
Severe Photosensitivity Reaction After Pirfenidone Use
title Severe Photosensitivity Reaction After Pirfenidone Use
title_full Severe Photosensitivity Reaction After Pirfenidone Use
title_fullStr Severe Photosensitivity Reaction After Pirfenidone Use
title_full_unstemmed Severe Photosensitivity Reaction After Pirfenidone Use
title_short Severe Photosensitivity Reaction After Pirfenidone Use
title_sort severe photosensitivity reaction after pirfenidone use
topic Family/General Practice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384726/
https://www.ncbi.nlm.nih.gov/pubmed/34458037
http://dx.doi.org/10.7759/cureus.16626
work_keys_str_mv AT choudhurysaiara severephotosensitivityreactionafterpirfenidoneuse
AT taweesedtpahnwatt severephotosensitivityreactionafterpirfenidoneuse
AT dadhwalrahul severephotosensitivityreactionafterpirfenidoneuse
AT suranisalim severephotosensitivityreactionafterpirfenidoneuse

Ejemplares similares